Rivaroxaban for deep-vein thrombosis treatment

• Pulmonary embolism masquerading as ST elevation myocardial infarction and ventricular tachycardia
• The Role of Direct Oral Anticoagulants (DOACs) in Cancer-Associated Thrombosis: A Comprehensive Review of the Literature
• Low molecular weight heparin calcium sequential rivaroxaban for the treatment of cerebral venous sinus thrombosis and cortical venous infarction in children with nephrotic syndrome: case report
• Use of Direct Oral Anticoagulants in Patients With Upper Extremity Deep Vein Thrombosis: A Meta-Analysis of Efficacy and Safety
• Rivaroxaban Treatment in Pediatric Patients With Hematologic Malignancies and Venous Thromboembolism: A Report of Four Cases
• A Protocol for Venous Thromboembolism Prophylaxis in Elective Spine Surgery: A Retrospective Evaluation of a Single-Center Experience
• Enhanced recovery and abbreviated length of anticoagulation for thromboprophylaxis after primary hip arthroplasty rationale and design of the ENABLE-hip trial
• Compassionate Use of Osocimab in Preventing Thrombotic Complications Without Incremental Bleeding: A Case Report

Initial Dosing: For the initial treatment of deep-vein thrombosis, rivaroxaban is typically started with a loading dose of 15 mg twice daily for the first 21 days.

Maintenance Dosing: After the initial period, the dose is usually reduced to 20 mg once daily for the maintenance phase.

Duration: The duration of treatment depends on individual risk factors and the clinical situation. It could range from a few months to longer, based on the risk of recurrence and other factors.

Monitoring: One of the advantages of rivaroxaban is that it does not require routine monitoring of anticoagulant levels, unlike some other anticoagulants.

Considerations: It's important to consider potential interactions with other medications and the patient’s kidney function, as rivaroxaban is contraindicated in severe renal impairment. Additionally, patients should be informed about the signs of bleeding and the need for regular follow-ups.